Cargando…

Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn’s Disease

BACKGROUND: Patients with Crohn’s disease (CD) are at risk of complications. Performance characteristics of a decision support tool assessing the risk of CD complications were evaluated. METHODS: CDPATH (formerly called the Personalized Risk and Outcome Prediction Tool [PROSPECT]) was calibrated and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siegel, Corey A, Siegel, Lori S, Dubinsky, Marla C, Targan, Stephan, Braun, Jonathan, Landers, Carol, Bilsborough, Janine, Princen, Fred, Lasch, Karen, Candela, Ninfa, McGovern, Dermot P B, Dervieux, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802159/ https://www.ncbi.nlm.nih.gov/pubmed/36777269 http://dx.doi.org/10.1093/crocol/otab074

Ejemplares similares

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Crohn’s Disease Patient Experiences and Preferences With Disease Monitoring: An International Qualitative Study
por: Rohatinsky, Noelle, et al.
Publicado: (2023)

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
por: Siegel, Corey A, et al.
Publicado: (2021)

Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn’s disease
por: Potdar, Alka A., et al.
Publicado: (2020)

The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease
por: Horrigan, Jamie M, et al.
Publicado: (2023)

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
por: Dubinsky, Marla C., et al.
Publicado: (2023)

Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
por: Hemperly, Amy, et al.
Publicado: (2021)

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
por: Yajnik, Vijay, et al.
Publicado: (2017)

Inflammatory Bowel Disease and Pain Interference: A Conceptual Model for the Role of Insomnia, Fatigue, and Pain Catastrophizing
por: Falling, Carrie L, et al.
Publicado: (2022)

Diagnostic and therapeutic potential of RNASET2 in Crohn’s disease: Disease-risk polymorphism modulates allelic-imbalance in expression and circulating protein levels and recombinant-RNASET2 attenuates pro-inflammatory cytokine secretion
por: Biener-Ramanujan, Eva, et al.
Publicado: (2022)

Crohn’s disease in endoscopic remission, obesity, and cases of high genetic risk demonstrates overlapping shifts in the colonic mucosal-luminal interface microbiome
por: Jacobs, Jonathan P., et al.
Publicado: (2022)

Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease
por: Potdar, Alka A., et al.
Publicado: (2021)

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
por: Papamichael, Konstantinos, et al.
Publicado: (2022)

Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers
por: Spencer, Elizabeth A, et al.
Publicado: (2020)

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
por: Dubinsky, Marla C, et al.
Publicado: (2022)

A Systematic Review of Fecal Microbiota Transplant for the Management of Pouchitis
por: Kayal, Maia, et al.
Publicado: (2020)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Fungal dysbiosis predicts the diagnosis of pediatric Crohn’s disease
por: El Mouzan, Mohammad I, et al.
Publicado: (2018)

A Novel Capsule Endoscopic Score for Crohn’s Disease
por: Omori, Teppei, et al.
Publicado: (2020)

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study
por: Matzkies, Franziska G, et al.
Publicado: (2012)

Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting
por: Rubin, David T., et al.
Publicado: (2020)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States
por: Siegel, Corey A., et al.
Publicado: (2020)

Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn’s disease
por: Gupta, Neera, et al.
Publicado: (2018)

Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
por: Sollelis, Elisa, et al.
Publicado: (2019)

Physical Activity in Adults With Crohn’s Disease: A Scoping Review
por: Neal, Whitney N, et al.
Publicado: (2022)

Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection
por: Long, Millie D, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn’s Disease
por: George, Alvin T, et al.
Publicado: (2023)

The Reliability of Patient Self-reported Utilization in an Inflammatory Bowel Diseases Learning Health System
por: van Deen, Welmoed K, et al.
Publicado: (2021)

Temporal trends in the misdiagnosis rates between Crohn’s disease and intestinal tuberculosis
por: Seo, Hyungil, et al.
Publicado: (2017)

Fecal MicroRNAs Show Promise as Noninvasive Crohn’s Disease Biomarkers
por: Wohnhaas, Christian T, et al.
Publicado: (2020)

Selective IgA(2) deficiency in a patient with small intestinal Crohn’s disease
por: Canales-Herrerias, Pablo, et al.
Publicado: (2023)

Family history and disease outcomes in patients with Crohn’s disease: A comparison between China and the United States
por: Wang, Pei-Qi, et al.
Publicado: (2016)

Non-invasive Serological Monitoring for Crohn’s Disease Postoperative Recurrence
por: Hamilton, Amy L, et al.
Publicado: (2022)

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients
por: Foster, Alice Jane, et al.
Publicado: (2019)

Simple pain measures reveal psycho-social pathology in patients with Crohn’s disease
por: Odes, Shmuel, et al.
Publicado: (2017)

Intestinal dysbiosis in pediatric Crohn's disease patients with IL10RA mutations
por: Xue, Ai-Juan, et al.
Publicado: (2020)

Comparison of cytokine and phosphoprotein profiles in idiopathic and Crohn’s disease-related perianal fistula
por: Haddow, James B, et al.
Publicado: (2019)

Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
por: Ramos, Guilherme Piovezani, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0t3e4ogsgrqqt9ulhsh518dl12